- Home
- NCZ vs OABI Comparison
NCZ vs OABI Comparison
Compare NCZ & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCZ | OABI |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.6M | 277.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NCZ | OABI |
|---|---|---|
| Price | $14.26 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 533.0K | ★ 573.1K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 12.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.36 |
| 52 Week Low | $2.50 | $1.22 |
| 52 Week High | $3.15 | $4.02 |
Technical Indicators
Market Signals| Indicator | NCZ | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 61.33 | 52.26 |
| Support Level | $13.75 | $1.81 |
| Resistance Level | $14.34 | $1.93 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 91.30 | 36.23 |
Price Performance
Historical ComparisonAbout NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.